+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

Acute Unilateral Vestibulopathy (AUV) - Pipeline Insight, 2025 - Product Thumbnail Image

Acute Unilateral Vestibulopathy (AUV) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Relapsing-Remitting Multiple Sclerosis - Pipeline Insight, 2025 - Product Thumbnail Image

Relapsing-Remitting Multiple Sclerosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Sensory Neuropathy - Pipeline Insight, 2025 - Product Thumbnail Image

Sensory Neuropathy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Leber's Hereditary Optic Neuropathy - Pipeline Insight, 2025 - Product Thumbnail Image

Leber's Hereditary Optic Neuropathy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Wilson Disease- Pipeline Insight, 2025 - Product Thumbnail Image

Wilson Disease- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Vascular Dementia - Pipeline Insight, 2025 - Product Thumbnail Image

Vascular Dementia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
5-HT2A Agonists - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT2A Agonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
5-HT1A Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT1A Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
5-HT2C Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT2C Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Kainate Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Kainate Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Alpha V Beta 3/5/6 Integrin Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Alpha V Beta 3/5/6 Integrin Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Alpha V Beta 3 Integrin Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Alpha V Beta 3 Integrin Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Alpha-1 Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Alpha-1 Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Alpha-1 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Alpha-1 Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Leukotriene D4 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Leukotriene D4 Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Alpha-2 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Alpha-2 Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
GABA Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

GABA Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Metabotropic Glutamate Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Metabotropic Glutamate Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
AMPA Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

AMPA Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more